Who
Jeremy M. Levin
Executive Chairman
Company insider
Files Form 4 as: Executive Chairman, Ovid Therapeutics; SVP Strat Transactions, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 60
- Buys
- 5
- Sells
- 0
- Bought
- $510K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Oct 2010
- Last trade
- 23 Mar 2026
- Last filed
- 25 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Mar 2026filed 25 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code M | $66K47,333 at $1.40 | filing |
| 23 Mar 2026filed 25 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,333 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,333 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code M | $66K47,333 at $1.40 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —957,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —957,000 at $0.00 | filing |
| 15 Dec 2025filed 18 Dec 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —71 at $0.00 | filing |
| 15 Dec 2025filed 18 Dec 2025 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code C | —71,000 | filing |
| 11 Dec 2025filed 18 Dec 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —71 | filing |
| 11 Dec 2025filed 18 Dec 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —47,333 | filing |
| 11 Dec 2025filed 18 Dec 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —35,500 | filing |
| 20 Feb 2025filed 24 Feb 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,650,000 at $0.00 | filing |
| 18 Mar 2024filed 20 Mar 2024 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K18,248 at $2.76 | filing |
| 22 Feb 2024filed 26 Feb 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 4 Dec 2023filed 6 Dec 2023 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code G | —573,275 at $0.00 | filing |
| 4 Dec 2023filed 6 Dec 2023 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code G | —573,275 at $0.00 | filing |
| 23 Feb 2023filed 27 Feb 2023 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 8 Apr 2022filed 12 Apr 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —423,244 at $0.00 | filing |
| 3 Feb 2022filed 4 Feb 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 17 Dec 2020filed 21 Dec 2020 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) and Perrigo (NYSE:PRGO) Head to Head ReviewOVID · themarketsdaily.com · 20 Oct 2026Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Overweight" in New Coverage at Cantor FitzgeraldOVID · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Jeremy M. Levin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.